Laurel Wealth Advisors (North Carolina)’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-625	Closed	-$1K	–	721
2022 Q1	$1K	Hold	625	–	–	﹤0.01%	665
2021 Q4	$1K	Hold	625	–	–	﹤0.01%	661
2021 Q3	$3K	Hold	625	–	–	﹤0.01%	575
2021 Q2	$5K	Buy	+625	New	+$4.43K	﹤0.01%	557

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s KLDO Position: Q2 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 625 shares — an estimated $1K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in KLDO in Q2 2021 and held it in 4 quarters. The position peaked at $5K in Q2 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

Laurel Wealth Advisors (North Carolina) reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 625 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $1K.
Laurel Wealth Advisors (North Carolina) first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
Laurel Wealth Advisors (North Carolina)'s Kaleido Biosciences, Inc. Common Stock position peaked at $5K in Q2 2021.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q2 2022, filed 12 Aug 2022.